CN110662767A - 使用人源化抗cxcr5抗体治疗狼疮 - Google Patents

使用人源化抗cxcr5抗体治疗狼疮 Download PDF

Info

Publication number
CN110662767A
CN110662767A CN201880033498.8A CN201880033498A CN110662767A CN 110662767 A CN110662767 A CN 110662767A CN 201880033498 A CN201880033498 A CN 201880033498A CN 110662767 A CN110662767 A CN 110662767A
Authority
CN
China
Prior art keywords
seq
ser
leu
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880033498.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·明
M·E·齐伯斯坦
R·卡里米·安德雷西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of CN110662767A publication Critical patent/CN110662767A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880033498.8A 2017-03-22 2018-03-22 使用人源化抗cxcr5抗体治疗狼疮 Pending CN110662767A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Publications (1)

Publication Number Publication Date
CN110662767A true CN110662767A (zh) 2020-01-07

Family

ID=61827719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033498.8A Pending CN110662767A (zh) 2017-03-22 2018-03-22 使用人源化抗cxcr5抗体治疗狼疮

Country Status (7)

Country Link
US (1) US20240207397A1 (https=)
EP (1) EP3601344A1 (https=)
JP (3) JP2020514386A (https=)
KR (2) KR20190131068A (https=)
CN (1) CN110662767A (https=)
AU (1) AU2018238540B2 (https=)
IL (2) IL318907A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
CN116075221A (zh) * 2020-04-21 2023-05-05 瑞泽恩制药公司 具有人源化cxcl13基因的非人动物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027266A1 (en) * 2007-08-29 2011-02-03 Sanofi-Aventis Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US20160053014A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen Binding Proteins that Bind CXCR5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027266A1 (en) * 2007-08-29 2011-02-03 Sanofi-Aventis Humanized anti-CXCR5 antibodies, derivatives thereof and their use
CN104017078A (zh) * 2007-08-29 2014-09-03 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
CN104017079A (zh) * 2007-08-29 2014-09-03 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
US20160053014A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen Binding Proteins that Bind CXCR5

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients", 《CLINICALTRIALS.GOV》, 3 June 2016 (2016-06-03) *
A WIENER等: "CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking", 《CLIN EXP IMMUNOL》, vol. 185, no. 1, 1 July 2016 (2016-07-01), pages 22 - 32 *
张学庸等: "《新编内科诊疗手册 第3版》", 31 August 2004, 金盾出版社, pages: 650 *
栗广林等: "《内科疾病诊治歌诀》", 31 March 1997, 河北科学技术出版社, pages: 262 *
王淑娟等: "《现代实验诊断学手册》", 31 August 1995, 中国协和医科大学联合出版社, pages: 436 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116075221A (zh) * 2020-04-21 2023-05-05 瑞泽恩制药公司 具有人源化cxcl13基因的非人动物
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof

Also Published As

Publication number Publication date
IL269419A (en) 2019-11-28
KR20250052493A (ko) 2025-04-18
JP2025087764A (ja) 2025-06-10
IL318907A (en) 2025-04-01
EP3601344A1 (en) 2020-02-05
JP2023040241A (ja) 2023-03-22
AU2018238540A1 (en) 2019-11-07
JP2020514386A (ja) 2020-05-21
KR20190131068A (ko) 2019-11-25
US20240207397A1 (en) 2024-06-27
AU2018238540B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
JP5926162B2 (ja) 炎症傷害の処置および評価
CN105960414A (zh) 治疗散发性包涵体肌炎的方法
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
TW201517917A (zh) 使用ｉｌ-１７拮抗劑治療類風濕性關節炎之方法
JP2025087764A (ja) ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
CN106397591A (zh) 骨关节炎治疗
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20240270873A1 (en) Dosing for anti-tryptase antibodies
KR20220066295A (ko) 항트립타제 항체의 투약
US12583929B2 (en) Method of treating acute respiratory distress syndrome
WO2023048651A1 (en) Method for treatment of moderate to severe atoptic dematitis
CN121909046A (zh) 脱发病症的治疗
TW202426494A (zh) 預測對ｉｌ－６拮抗劑的反應
TW202540182A (zh) 用於治療代謝疾病之新穎抗體和抗體共軛體
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
EP4408465A1 (en) Method for treatment of moderate to severe atoptic dematitis
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法
CN118103069A (zh) 治疗中度至重度特应性皮炎的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination